Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

177 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Micro-costing diagnostics in oncology: from single-gene testing to whole- genome sequencing.
Pasmans CTB, Tops BBJ, Steeghs EMP, Coupé VMH, Grünberg K, de Jong EK, Schuuring EMD, Willems SM, Ligtenberg MJL, Retèl VP, van Snellenberg H, de Bruijn E, Cuppen E, Frederix GWJ. Pasmans CTB, et al. Expert Rev Pharmacoecon Outcomes Res. 2021 Jun;21(3):413-414. doi: 10.1080/14737167.2021.1917385. Epub 2021 May 6. Expert Rev Pharmacoecon Outcomes Res. 2021. PMID: 33852815
Early Cost Effectiveness of Whole-Genome Sequencing as a Clinical Diagnostic Test for Patients with Inoperable Stage IIIB,C/IV Non-squamous Non-small-Cell Lung Cancer.
Simons MJHG, Retèl VP, Ramaekers BLT, Butter R, Mankor JM, Paats MS, Aerts JGJV, Mfumbilwa ZA, Roepman P, Coupé VMH, Uyl-de Groot CA, van Harten WH, Joore MA. Simons MJHG, et al. Pharmacoeconomics. 2021 Dec;39(12):1429-1442. doi: 10.1007/s40273-021-01073-y. Epub 2021 Aug 18. Pharmacoeconomics. 2021. PMID: 34405371 Free PMC article.
A Micro-Costing Framework for Circulating Tumor DNA Testing in Dutch Clinical Practice.
Kramer A, Schuuring E, Vessies DCL, van der Leest P, Geerlings MJ, Rozendal P, Lanfermeijer M, Linders TC, van Kempen LC, Fijneman RJA, Ligtenberg MJL, Meijer GA, van den Broek D, Retèl VP, Coupé VMH; COIN Consortium. Kramer A, et al. J Mol Diagn. 2023 Jan;25(1):36-45. doi: 10.1016/j.jmoldx.2022.10.004. Epub 2022 Nov 17. J Mol Diagn. 2023. PMID: 36402278 Free article.
Exploring the Cost Effectiveness of a Whole-Genome Sequencing-Based Biomarker for Treatment Selection in Patients with Advanced Lung Cancer Ineligible for Targeted Therapy.
Mfumbilwa ZA, Simons MJHG, Ramaekers B, Retèl VP, Mankor JM, Groen HJM, Aerts JGJV, Joore M, Wilschut JA, Coupé VMH. Mfumbilwa ZA, et al. Among authors: coupe vmh. Pharmacoeconomics. 2024 Apr;42(4):419-434. doi: 10.1007/s40273-023-01344-w. Epub 2024 Jan 9. Pharmacoeconomics. 2024. PMID: 38194023 Free PMC article.
Early evaluation of the effectiveness and cost-effectiveness of ctDNA-guided selection for adjuvant chemotherapy in stage II colon cancer.
Kramer A, Greuter MJE, Schraa SJ, Vink GR, Phallen J, Velculescu VE, Meijer GA, van den Broek D, Koopman M, Roodhart JML, Fijneman RJA, Retèl VP, Coupé VMH. Kramer A, et al. Among authors: coupe vmh. Ther Adv Med Oncol. 2024 Aug 21;16:17588359241266164. doi: 10.1177/17588359241266164. eCollection 2024. Ther Adv Med Oncol. 2024. PMID: 39175989 Free PMC article.
177 results